Entering text into the input field will update the search result below

J&J files application in Europe for expanded use of Spravato

Jan. 15, 2020 7:56 AM ETJohnson & Johnson (JNJ)JNJBy: Douglas W. House, SA News Editor
  • Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has filed a supplemental marketing application in Europe, called a Type II variation, seeking approval to use Spravato (esketamine) nasal spray as an acute short-term treatment, together with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults experiencing a moderate-to-severe depressive episode of major depressive disorder (MDD) who have suicidal ideation with intent.
  • Spravato is currently approved (December 2019) in the EU for adults with treatment-resistant MDD, in combination with an SSRI or SNRI, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.